| Entry |
|
|---|
| Name |
Erlizumab (USAN/INN) |
|---|
| Efficacy |
Immunosuppressant, Anti-CD18 antibody |
|---|
| Type |
Monoclonal antibody |
|---|
| Comment |
Adjunctive treatment to reperfusion therapy in acute myocardial infarction or other types of reperfusion therapy
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04650 | Natural killer cell mediated cytotoxicity |
| hsa04670 | Leukocyte transendothelial migration |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: other families
Integrins
ITGB2/ITGAL
D04045 Erlizumab (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
